El grande iio de David Cristo Señor nuestro : istoria evangelica, moral, politica, y predicable, adornada con raros exenplos, y prodigiosos casos conpuesta, por el Padre ... Fr. Antonio de Lorea... ; dada a la estampa por ... D. Bernardo de Lorea Amescua... ; tomo quinto

Marca tip. en port. orladaTexto a dos col.ColofónPerg.¶8, A-Z8, Aa-Bb

El grande iio de David, Cristo Señor nuestro : istoria evangelica, moral, politica, y predicable conpuesta, por el P. ... Fr. Antonio de Lorêa... ; dada a la estanpa, por ... don Bernardo de Lorêa Amescua... ; tomo segundo

Marca tip. en port. orladaTexto a dos colPerg.¶4, ¶¶2, A-Z8, Aa2, §

Dauid perseguido : primera parte

Marca tip. en port.Sign.: [parágrafo]>84884<.Errores de pag., las p. 243-246 repetidas, y las p. 251-256 repetidas.Texto a dos col

Dauid perseguido : segunda parte, istorica, moral, y politica

Marca tip. en port.Sign.: [parágrafo]>888422<

Low-dose statin treatment increases prostate cancer aggressiveness

Altres ajuts: NM-M was supported by the Spanish Association Against Cancer (AECC), AECC JP Vizcaya. VT is supported by Fundación Vasca de Innovación e Investigación Sanitarias, BIOEF (BIO15/CA/052), the department of health of the Basque Government (2016111109) and the 2016 grant of the AECC (Junta provincial de Bizkaia). LA, AA-A and LV-J were supported by the Basque Government of education. The work of A.C. is supported by the Ramón y Cajal award, the Basque Department of Industry, Tourism and Trade (Etortek) and the department of education (IKERTALDE IT1106-16), FERO VIII Fellowship, the BBVA foundation, Severo Ochoa. Excellence Accreditation SEV-2016-0644) and the European Research Council (Starting Grant 336343; Proof of Concept 754627). The participation of AC, VT, NM-M, SF and AZ as part of CIBERONC was co-funded with FEDER funds.Prostate cancer is diagnosed late in life, when co-morbidities are frequent. Among them, hypertension, hypercholesterolemia, diabetes or metabolic syndrome exhibit an elevated incidence. In turn, prostate cancer patients frequently undergo chronic pharmacological treatments that could alter disease initiation, progression and therapy response. Here we show that treatment with anti-cholesterolemic drugs, statins, at doses achieved in patients, enhance the pro-tumorigenic activity of obesogenic diets. In addition, the use of a mouse model of prostate cancer and human prostate cancer xenografts revealed that in vivo simvastatin administration alone increases prostate cancer aggressiveness. In vitro cell line systems supported the notion that this phenomenon occurs, at least in part, through the direct action on cancer cells of low doses of statins, in range of what is observed in human plasma. In sum, our results reveal a prostate cancer experimental system where statins exhibit an undesirable effect, and warrant further research to address the relevance and implications of this observation in human prostate cancer

Genetic manipulation of LKB1 elicits lethal metastatic prostate cancer

Gene dosage is a key defining factor to understand cancer pathogenesis and progression, which requires the development of experimental models that aid better deconstruction of the disease. Here, we model an aggressive form of prostate cancer and show the unconventional association of LKB1 dosage to prostate tumorigenesis. Whereas loss of Lkbl alone in the murine prostate epithelium was inconsequential for tumorigenesis, its combination with an oncogenic insult, illustrated by Pten heterozygosity, elicited lethal metastatic prostate cancer. Despite the low frequency of LKB1 deletion in patients, this event was significantly enriched in lung metastasis. Modeling the role of LKB1 in cellular systems revealed that the residual activity retained in a reported kinase-dead form, LKB1(K781), was sufficient to hamper tumor aggressiveness and metastatic dissemination. Our data suggest that prostate cells can function normally with low activity of LKB1, whereas its complete absence influences prostate cancer pathogenesis and dissemination

Treatment with tocilizumab or corticosteroids for COVID-19 patients with hyperinflammatory state: a multicentre cohort study (SAM-COVID-19)

Objectives: The objective of this study was to estimate the association between tocilizumab or corticosteroids and the risk of intubation or death in patients with coronavirus disease 19 (COVID-19) with a hyperinflammatory state according to clinical and laboratory parameters. Methods: A cohort study was performed in 60 Spanish hospitals including 778 patients with COVID-19 and clinical and laboratory data indicative of a hyperinflammatory state. Treatment was mainly with tocilizumab, an intermediate-high dose of corticosteroids (IHDC), a pulse dose of corticosteroids (PDC), combination therapy, or no treatment. Primary outcome was intubation or death; follow-up was 21 days. Propensity score-adjusted estimations using Cox regression (logistic regression if needed) were calculated. Propensity scores were used as confounders, matching variables and for the inverse probability of treatment weights (IPTWs). Results: In all, 88, 117, 78 and 151 patients treated with tocilizumab, IHDC, PDC, and combination therapy, respectively, were compared with 344 untreated patients. The primary endpoint occurred in 10 (11.4%), 27 (23.1%), 12 (15.4%), 40 (25.6%) and 69 (21.1%), respectively. The IPTW-based hazard ratios (odds ratio for combination therapy) for the primary endpoint were 0.32 (95%CI 0.22-0.47; p < 0.001) for tocilizumab, 0.82 (0.71-1.30; p 0.82) for IHDC, 0.61 (0.43-0.86; p 0.006) for PDC, and 1.17 (0.86-1.58; p 0.30) for combination therapy. Other applications of the propensity score provided similar results, but were not significant for PDC. Tocilizumab was also associated with lower hazard of death alone in IPTW analysis (0.07; 0.02-0.17; p < 0.001). Conclusions: Tocilizumab might be useful in COVID-19 patients with a hyperinflammatory state and should be prioritized for randomized trials in this situatio

El grande iio de David, Cristo ... : istoria evangelica, Moral, Política, y Predicable, adornada con raros exemplos, y prodigiosos casos ...

Copia digital. España : Ministerio de Cultura y Deporte. Subdirección General de Coordinación bibliotecaria, 2018Marca tipográfica del editor en portadaPortada orladaTexto a dos col

Vita mirabilis & mors pretiosa venerabilis sororis Rosae de S. Maria Limensis, ex tertio ordine S.P. Dominici. Español

[16], 224, [4] h. : il. ; 4

Emiuentisse. et Rme. Domine, & Sacra Rituum Congregatio. Ad pedes V. Eminentiae Fr. Antonius de Lorèa... Novit Ecclesia, Eminentis, & Reverendissime Pater, imo & novèrunt, qui extra eam fuere, Sanctum Raymundum de Peñafort..

A 111/090(27